Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Under Armour Inc Class A — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B), while Under Armour Inc Class A trades at $4.89 (market cap $2.05B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 28.4× Under Armour Inc Class A's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days and Under Armour Inc Class A for 99 Days on average.
| TAK | UAA | |
|---|---|---|
Market Cap | $58.16B | $2.05B |
Volume | 2,467,530 | 13,461,776 |
Sector | Health | Consumer Cyclical |
52-Week High | $19.05 | $8.14 |
52-Week Low | $13.23 | $4.17 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $86.04B | $3.03B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Under Armour (UAA) trades at $4.88 with no change in the latest session. The stock shows mixed signals with a bullish technical outlook but faces fundamental challenges including negative net income margin of -9.99% and declining revenue trends from $5.7B in 2024 to $5.2B in 2025. Recent earnings showed beats in Q4 2025 and Q2 2026 but a miss in Q1 2026. The company is undergoing brand transformation with product focus shifts amid softer demand.
Investment outlook remains cautious with analyst consensus at Buy (27%) but significant Hold ratings (57%). The $5.79 price target suggests 19% upside potential. Key risks include persistent revenue weakness, negative cash flow trends, and competitive pressures in the athletic apparel sector. Margin improvements offer potential upside if demand recovers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
